High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir

AIDS

Volumn 19, Issue 15, 2005, Pages 1695-1697

  Leon, Agathe ^a   Mallolas, Josep ^a   Martinez, Esteban ^a   De Lazzari, Elisa ^a   Pumarola, Tomás ^a   Larrousse, María ^a   Milincovic, Ana ^a   Lonca, Montserrat ^a   Blanco, Jose Luis ^a   Laguno, Montserrat ^a   Biglia, Alejandra ^a   Gatell, Josep María ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; TIME SERIES ANALYSIS; TREATMENT OUTCOME; VIROLOGY; VIRUS IDENTIFICATION;

EID: 27144439146     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000186821.30489.16     Document Type: Article

References (12)

1. Podzamczer D, Ferrer E, Gatell JM, Niubo J, Dalmau D, León A, et al. Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antiviral Ther 2005; 10:171-177.
2. León A, Martinez E, Mallolas J, Laguno M, Blanco JL, Pumarola T, et al. Early virological failure in treatment naive HIV-infected adults receiving efavirenz or nevirapine plus didanosine and tenofovir. AIDS 2005; 19:9-11.
3. Moyle G, Maitland D, Hand J, Mandalia S, Nelson M, Gazzard B. Early virological failure in persons with viral loads > 100000 copies/ml and CD4 counts < 200/mm3 receiving didanosine/tenofovir/efavirenz as initial therapy: 12 week results from a randomized comparative trial. Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, November 2004 [Abstract H-566].
4. Martinez E, Milinkovic A, De Lazzari E, Ravasi G, Blanco JL, Larrousse M, et al. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet 2004; 364:8-10.
5. Barrios A, Rendon A, Negredo E, Barreiro P, Garcia-Benayas T, Labarga P, et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS 2005; 19:569-575.
6. The European Agency for the Evaluation of Medicinal Products. EMEA/62331/2005. London: EMEA; 3 March 2005.
7. Johnson VA, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV: 2005. Topics HIV Med 2004; 13:51-57.
8. Hoogewerf M, Regez RM, Schouton WEM, Weigel HM, Frissen PHG, Brinkman K. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Lancet 2003; 13:1979-1980.
9. Perez-Elias MJ, Moreno S, Gutierrez C, Lopez D, Abraira V, Moreno A, et al. High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir. AIDS 2005; 19:695-698.
10. Katlama C, Fenske S, Gazzard B, Lazzarin A, Clumeck N, Mallolas J, et al. TRIZAL study: switching from successful HAART to trizivir: 48 weeks efficacy, safety and adherence results. HIV Med 2003; 4:79-86.
11. Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al., for the NEFA Study Team. Substitution of nevirapine, efavirenz or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349:1036-1046.
12. Study of treatment-experienced HIV patients with a combination antiretroviral regimen containing a RTV-boosted PI, TDF and didanosine EC or another NRTI. BMS Study AI424-0457. Data on file, Bristol-Myers Squibb Company, Princeton, New Jersey, USA.